See LEGEND for key to shading and symbols.
Subject Area - PHAR Term - Term 3 2019
PHAR2011 | PHAR3101 | PHAR9104 | PHAR9115 | PHAR9117 | PHAR9121 |
PHAR9124 | PHAR9130 (AFB) |
Data is correct as at Mon 23 Sep 13:05:23 AEST 2019
Comp | Sect | Class | Type | Status | Enr/Cap | % Full | Times (weeks, Location) - default 1hour |
PHAR2011 | Introductory Pharmacology and | ||||||
CRS | CR01 | 1791 | Open | 0/8 | 0% | (Course Enrolment, UGRD) | |
LAB | T10A | 5332 | Enr | Full | 85/85 | 100% | Tue 10-13 (w1,3,5,7,9, Wurth 115) |
LAB | T10B | 5333 | Enr | Full | 85/85 | 100% | Tue 10-13 (w2,4,8,10, Wurth 115); Tue 10-13 (w1, Wurth 116) |
LAB | T14A | 5334 | Enr | Open | 69/70 | 99% | Tue 14-17 (w1,3,5,7,9, Wurth 115) |
LAB | T14B | 5335 | Enr | Open | 63/85 | 74% | Tue 14-17 (w2,4,8,10, Wurth 115); Tue 14-17 (w1, Wurth 116) |
LEC | A | 5321 | Rel | Open | 302/325 | 93% | Thu 17 (w1-10, PhysicsTh); Fri 15 (w1-10, MathewsThA) |
TUT | F13A | 5322 | Rel | Full | 31/31 | 100% | Fri 13 (w1-10, Mat 227) |
TUT | F13B | 5323 | Rel | Full | 31/31 | 100% | Fri 13 (w1-10, Mat 308) |
TUT | F14A | 5324 | Rel | Full | 31/31 | 100% | Fri 14 (w1-10, Mat 227) |
TUT | F14B | 5325 | Rel | Full | 31/31 | 100% | Fri 14 (w1-10, Mat 308) |
TUT | H14A | 5326 | Rel | Full | 31/31 | 100% | Thu 14 (w1-10, Mat 227) |
TUT | H14B | 5327 | Rel | Full | 31/31 | 100% | Thu 14 (w1-10, Mat 226) |
TUT | H15A | 5328 | Rel | Full | 31/31 | 100% | Thu 15 (w1-10, Mat 226) |
TUT | H15B | 5329 | Rel | Full | 31/31 | 100% | Thu 15 (w1-10, Mat 227) |
TUT | H16A | 5330 | Rel | Open | 28/31 | 90% | Thu 16 (w1-10, Mat 106) |
TUT | H16B | 5331 | Rel | Open | 26/31 | 84% | Thu 16 (w1-10, Mat 108) |
PHAR3101 | Drug Discovery, Design & Devel | ||||||
CRS | CR01 | 1785 | Open | 0/6 | 0% | (Course Enrolment, UGRD) | |
LAB | W15A | 6128 | Rel | Open | 62/68 | 91% | Wed 15-18 (w1-10, Wurth 115) |
LEC | A | 6125 | Enr | Open | 62/68 | 91% | Wed 13 (w1-10, TETB LG07); Fri 12 (w1-10, ChemSc M10) |
TUT | F15A | 6126 | Rel | Full | 34/34 | 100% | Fri 15 (w1-10, Mat 106) |
TUT | F16A | 6127 | Rel | Open | 28/34 | 82% | Fri 16 (w1-10, Mat 106) |
PHAR9104 | Regulatory Affairs | ||||||
CRS | CR01 | 1099 | Open | 0/15 | 0% | (Course Enrolment, PGRD) | |
DST | A | 9887 | Enr | Open | 15/30 | 50% | |
PHAR9115 | Advanced HTA | ||||||
CRS | CR01 | 1100 | Canc | 0/0 | N/A | (Course Enrolment, PGRD) | |
PHAR9117 | Cancer Therapeutics | ||||||
CRS | CR01 | 1173 | Open | 0/19 | 0% | (Course Enrolment, PGRD) | |
DST | A | 9785 | Enr | Open | 11/30 | 37% | |
PHAR9121 | Pharmacovigilance | ||||||
CRS | CR01 | 1015 | Open | 0/6 | 0% | (Course Enrolment, PGRD) | |
DST | A | 9786 | Enr | Open | 24/30 | 80% | |
PHAR9124 | Internship | ||||||
CRS | CR01 | 1073 | Open* | 0/3 | 0% | (Course Enrolment, PGRD) | |
DST | A | 9787 | Enr | Open | 2/5 | 40% | |
PHAR9130 | Pharmaceutical GRA Leadership (AFB) | ||||||
CRS | CR01 | 10173 | Open* | 0/30 | 0% | (Course Enrolment, PGRD) | |
DST | A | 10181 | Enr | Open | 0/30 | 0% | |
^ top ^ | |||||||
LEGEND | |||||||
* This class requires consent. Students cannot self-enrol. | |||||||
# Timetable clash allowed. | |||||||
/odd Runs in odd weeks only. /even Runs in even weeks only. | |||||||
Comb/w Jointly taught with corresponding class(es) for specified course(s). Capacity shown is effective capacity. | |||||||
Effective capacity is the class capacity less any places taken by students in the other jointly-taught classes. | |||||||
[ ] Class capacity where different from effective capacity. | |||||||
Shaded cells: | LEC | Activity different from previous | |||||
Stop | Status is Stop Further Enrolment, Tentative, Closed or Cancelled | ||||||
100% | Class is full (> 100% means capacity is exceeded) | ||||||
80% | Class is nearly full (80% or more) | ||||||
50% | Class is half full | ||||||
0% | Class is less than half full | ||||||
UNSW Sydney NSW 2052, Australia Telephone: (within Aust.) 02 9385 1000, (International) +61 2 9385 1000 CRICOS Provider Code 00098G ABN: 57 195 873 179 Authorised by Vice-President and Deputy Vice-Chancellor (Academic) Privacy Policy Copyright & Disclaimer Accessibility |